Kessler Jon

Kessler Jon sells 231,950 shares (75.6% of holdings) at $112.06 avg on HQY; 1 of 5 prior same-ticker sales were well-timed

Jon Kessler executed 9 separate sales totaling 231,950 shares for $25,992,976.67 on 2025-06-06, reducing his holdings to 75,000 shares post-transaction and representing a 75.6% reduction in his position. The blended average price of $112.06 sits 1.4% above the current price of $107.22 and 2.1% below the 52-week high of $114.51. His cross-ticker track record shows a 75.00% well-timed rate across 20 prior sells with an average 90-day return of -2.2%, but at HQY specifically, only 1 of 5 prior sales (20%) were well-timed at the 90-day mark, with the September 2024 sales followed by gains of 21.1–22.1% and the June 2024 sale followed by a -4.7% decline. This sale—a substantial liquidation at near-peak valuations—follows a pattern of underperformance in his same-ticker transaction history, providing limited confidence in the timing quality of this position reduction.

CEO Kessler sells 29,749 shares (29.7K) for $2.3M at blended $78.42; holds 101.2K post-sale.

Jon Kessler, President and CEO of HealthEquity, executed 4 separate sales totaling 29,749 shares for $2,332,992.92 on September 16, 2024, reducing his holdings by 22.7% to 101,235 shares. The blended average price of $78.42 sits above the current price of $77.54, indicating the execution was modestly favorable in the immediate context. Kessler's cross-ticker track record shows a 90% well-timed rate across 16 prior sells with an average 90-day return of -10.3%, suggesting consistent ability to sell ahead of declines; however, his same-ticker history at HQY comprises only 5 prior trades (all sells from June 2024) with no measurable 90-day outcomes yet. The stock's 30-day performance is +2.4% while the 90-day change is -5.7%, placing the stock near its 52-week high range of $62.44–$86.94. With a P/E of 64.08, HealthEquity trades at a premium multiple despite 16% annual revenue growth and $35.8M quarterly net income.

HQY CEO Kessler sold 55,251 shares ($4.6M) across 6 transactions on 2024-06-24/25 at blended avg $82.87, reducing holdings by 33.4%.

Jon Kessler, HQY's President and CEO, executed 6 separate sales totaling 55,251 shares for $4,578,579.37 over two trading days, reducing his post-transaction holdings to 109,985 shares—a 33.4% reduction in his stake. The sales occurred near the 52-week high ($86.94), with the blended average transaction price of $82.87 positioned only 0.07% above the current price of $82.81. Kessler's cross-ticker track record shows a 90.00% well-timed rate on 10 prior sells with an average 90-day return of -10.3%, and at HQY specifically, 4 of 5 prior sales were well-timed at the 90-day mark. The large absolute dollar volume and substantial reduction in his ownership stake—moving from 165,236 to 109,985 shares—represent material changes in his personal portfolio positioning at a time when HQY's valuation metrics (P/E: 90.01) remain elevated and growth moderates in context of recent positive momentum (30-day: +4.5%). Without a disclosed 10b5-1 plan or other scheduling FLAG, this concentrated liquidation warrants examination of whether it reflects considerations about near-term equity valuation or capital allocation priorities by the company's chief executive.